| Name | Title | Contact Details |
|---|---|---|
Meredith Harper |
CISO Advisor | Profile |
SMSI is a small business providing management and technical/engineering services to the DOE/NNSA, national laboratories, and industrial clients. Our work with nuclear facility operations and safety has set the standard for excellence. We are the resource for highly technical engineering and nuclear safety basis development, review, and implementation at the national laboratories. SMSI has a demonstrated record of success providing superior people developing and implementing innovative solutions, delivering projects on time and within budget. We build productive relationships by being highly responsive to our customers. Operations began in 2000 with headquarters in Albuquerque, NM, and currently operating offices in Los Alamos, NM and Oak Ridge, TN.
Diamond Baseball Holdings (DBH) is a New York-based company founded in 2021 that owns and operates a significant portfolio of Minor League Baseball (MiLB) clubs affiliated with Major League Baseball. The company focuses on professional management, best practices, and innovative investments to enhance fan experiences, brand engagement, player conditions, and community impact. As of 2024, DBH has acquired 33 teams, making it one of the largest ownership groups in MiLB history. The company emphasizes maintaining baseballs traditions while upgrading facilities and improving player welfare. DBH operates as part of Silver Lakes sports investments and applies private equity strategies to enhance operations and achieve market-beating returns. Its initiatives include partnerships for stadium upgrades and innovations aimed at boosting fan attendance and creating superior environments for both fans and players.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Corporate Fleet Services specializes in the acquisition and sale of corporate jets. We have successfully completed hundreds of transactions Nationally and Internationally. It is rare that a Dealer can inventory the large corporate jets required in todays business environment. Few are in the position to structure the leasing, purchasing or delayed purchase options we offer. In addition to purchasing and selling aircraft, Corporate Fleet Services can act as your exclusive agent to either purchase or sell your current aircraft. Our research department is updating its files daily to stay ahead of market trends.